top of page
Companies in the News
eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company
Common stock and warrants expected to commence trading on Nasdaq on August 26, 2021 under the ticker symbols EFTR and EFTRW SAN DIEGO,...
Aug 25, 2021
BiotechBayer bets $1.5B that Vividion will help it target the 'undruggable' and make 1+1=3
Sometimes, it takes $1.5 billion to make "one plus one equal three." Bayer wanted to "really transform" its R&D engine under its recently...
Aug 5, 2021
Ring Therapeutics Raises $117 Million in Series B Funding to Expand Novel Vector Platform
Ring's novel vector Anellogy™ platform harnesses unique properties of anelloviruses to create a pipeline of redosable vectors compatible...
Jul 28, 2021
Pacific Biosciences Signs Definitive Agreement to Acquire Omniome
Combination aims to transform the genomics landscape and deliver a differentiated product offering into high growth clinical markets...
Jul 20, 2021
Vividion Therapeutics Files for IPO
Vividion Therapeutics Inc., a biotechnology company that seeks to develop drugs for cancer and immune disorders using "traditionally...
Jun 25, 2021
Tempest and Millendo Announce Stockholder Approval of Merger
Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST” SOUTH SAN FRANCISCO, Calif. and ANN ARBOR, Mich., June 22, 2021 (GLOBE...
Jun 22, 2021
Lyell Immunopharma Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming...
Jun 17, 2021
MorphoSys to buy Constellation Pharma for $1.7 billion; Constellation's stock soars 61%
Shares of MorphoSys AG ADR MOR, -12.90% were down 8.9% in premarket trading on Wednesday after the company announced a $1.7 billion...
Jun 2, 2021
eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement
Gross proceeds expected to include $60 million from a committed PIPE and up to $175 million held in trust Anticipated cash resources will...
May 27, 2021
bottom of page